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We have recently read with great interest the editorial
authored by Cáceres-Lóriga et al.1 The authors summarized
the etiopathogenesis, diagnosis, and management of pros-
thetic valve thrombosis (PVT). We want to make several
essential comments about the role of thrombolytic therapy
(TT) in the management of PVT.
Despite technological advancements, the hemodynamic
and physical properties of mechanical valves remain thrombo-
genic and patients with prosthetic heart valves, therefore, are
prone to developing PVT.2 There are different therapeutic
modalities for PVT including anticoagulation with heparin,
TT,3–6 and surgery7which are largely inﬂuenced by the presence
of valvular obstruction, by valve location, and by clinical
features.
Despite the improvement in mortality over the past decade,
surgical management of PVT has been associated with a
signiﬁcant death risk for 40 years. Therefore, establishment of
a more effective strategy to treat PVT is crucial, especially in
the developing countries where this condition is prevalent.5
TT studies for PVT have shown much promise, with the results
suggesting that such treatment modality might be the initial
choice in these patients. Unfortunately, randomized con-
trolled trials to address this management decision are lacking.
Recently, several meta-analyses and systematic reviews
have been published. Karthikeyan and colleagues8 evaluated
seven studies with 690 episodes of PVT (446 treated with
surgery and 244 with TT) and found no signiﬁcant differences
in the main outcome (restoration of valve functions) between
patients treated surgically and TT. They stated that urgent
surgery should probably be preferred over TT in experiencedcenters. On the other hand, Castilho et al.7 reported much
higher mortality rates with surgery compared with TT in the
management of PVT (18.1% vs. 6.6%, respectively). Recently,
our group5,6 has reported two studies which have shown the
incremental role of TT in the management of PVT.
The TROIA study5 which includes the largest cohort
published to date, evaluated a strategy of transesophageal
echocardiography (TEE)-guided ﬁbrinolysis with rapid infusion
of streptokinase (Group I) versus slow infusion of streptokinase
(Group II) versus full-dose tissue plasminogen activator (t-PA)
(100 mg) (Group III) versus half dose (50 mg) slow infusion of
t-PA (Group IV) versus low dose (25 mg) slow infusion of t-PA
(Group V). This was a monocentric, prospective, non-random-
ized study. The authors suggested that lower dose, TEE-guided,
repeated, slow administration of a ﬁbrinolytic agent could be
equally efﬁcacious with fewer complications. This was also
conﬁrmed in the PROMETEE trial6which showed that ultra-slow
(25 h) infusion of low dose (25 mg) t-PA without bolus was
associated with quite low non-fatal complications and mortali-
ty for PVT patients except for those with NYHA class-IV, without
compromising effectiveness. On the basis of these ﬁndings tPA,
a ﬁbrin-speciﬁc agent seems to be very effective.5,6 A similar
beneﬁt with intravenous bolus dose of tenecteplase has also
been recently reported,9 but it should be acknowledged that
although accelerated TT protocols may achieve more rapid lysis
of the thrombus, they pose an essential risk for complications
such as thromboembolism and hemorrhage. In TROIA study,5
the rate of intracranial bleed was 0.8% in PVT patients
undergoing low-dose (t-PA strategy). In PROMETEE study,6 none
of the patients suffered intracranial hemorrhage and the non-
cerebral major bleeding rate was also quite low (1.7%).
As Cáceres-Lóriga et al.1 have stated in the present
editorial, both transthoracic echocardiography and TEE are
indispensable guides for evaluation of leaﬂet immobilization,
cause of underlying pathology (thrombus versus pannus or
both), and whether TT attempt in the patient would be
successful or surgery is needed.10–12 These modalities enhance
clinical decision making in patients with suspected PVT.
Consequently, on the basis of recent evidences and our 20-
year experience, we think TT (slow-dose and prolonged
infusion) under TEE guidance has proven its efﬁcacy with a
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ﬁrst-line therapy in the management of PVT.
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